The New Outlook of Monoclonal Antibodies in Neutralizing Target Cells in COVID-19
Background: The deadly arrival of novel coronavirus (COVID-19) in late December 2019, caused by the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) has emerged worldwide causing a pandemic. The World Health Organization (WHO) has proved ineffectiveness against existing medications this influenced the prompt identification of Monoclonal antibodies (mAbs) which plays a vital role as the prophylactic application that helps in developing new interventions.
Objectives: To study the effect of mAbs in high-risk individuals in treating COVID-19.
Methodology: The recent studies related to the aim of the review were undertaken through a literature search to analyze the importance of mAbs in combating SARS-CoV-2.
Results: In several countries even though vaccines have reached the Emergency Use Authorization (EUA) people still rely on traditional medications. Besides repurposed drugs, recently many mAbs targeting S-protein of SARS-CoV-2 have been signed up for clinical trials. Currently, no specific neutralizing mAbs have been reported for SARS-CoV-2 and it may take several years for such antibodies to be readily available. The development of mAbs for preventing the SARS-CoV 2 infection is challenged by the threat of antibody-dependent enhancement, antibody-resistant against SARS-CoV-2 variants, acute respiratory infections, clinical trials and risk assessment, and inexplicable. The clinical trial data proved that there is no life-threatening Adverse Drug Reactions (ADR) occurred during mAbs therapy for COVID-19 patients.
Conclusion: Establishing monoclonal antibodies will continue to be the best prophylactic application as it minimizes the risk of hospitalization in the high-risk individuals affected by SARS-CoV-2 infection.
Keywords: COVID-19, Monoclonal antibodies (mAbs), Emergency Use Authorization (EUA), Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2)
2. Waldmann TA, Strober W. Metabolism of immunoglobulins. Prog Allergy. 1969; 13:1-110. https://doi.org/10.1159/000385919
3. Llewelyn MB, Hawkins RE, Russell SJ, et al. Discovery of antibodies. BMJ. 1992; 305: 1269-1272. https://doi.org/10.1136/bmj.305.6864.1269
4. Behring EA, Kitasato S. Ueber das Zustandekommen der Diphtherie-immunitat und der Tetanus-immunitat bei Thieren. Dtsch. Med. Wochenschr. 1890; 28:1321-1332.
5. Hung IF, To KK, Lee Ck, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin. Infect. Dis. 2011; 52(4):447-456. https://doi.org/10.1093/cid/ciq106
6. Jenkins JM, Campos MS, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J. Infect. Dis.2015; 211(1):80-90. https://doi.org/10.1093/infdis/jiu396
7. Kim PS, Read SW, Fauci AS, et al. Therapy for early COVID-19: a critical need. JAMA. 2020; 324(21):2149-2150.. https://doi.org/10.1001/jama.2020.22813
8. Walls AC, Park YJ, Tortorici MA, et al. Structure, Function and Antigenicity of the SARS-COV-2 Spike Glycoprotein. Cell. 2020; 181(2):281-292. https://doi.org/10.1016/j.cell.2020.02.058
9. X SL, Moreno MT, Ramilo O, et al. Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection. Pediatr. Infect. Dis. J. 2004; 23(8):707-712. https://doi.org/10.1097/01.inf.0000133165.85909.08
10. Malley R, Romilo O, Gruber WC, et al. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J. Infect. Dis. 1998; 178(6):1555-1561. https://doi.org/10.1086/314523
11. Zhou P, Yang X, Wang X, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. https://doi.org/10.1038/s41586-020-2012-7
12. Marston HD, Paules CI, Fauci AS. Monoclonal antibodies for emerging infectious diseases-borrowing from history. N Engl J Med. 2018; 378(16):1469-1472. https://doi.org/10.1056/NEJMp1802256
13. Tillett R, Sevinsky J, Hartley P, et al. Genomic evidence for reinfection with SARS-CoV-2: a case study. Lancet Infect Dis. 2020; 21(1):52-58. https://doi.org/10.1016/S1473-3099(20)30764-7
14. Pan H, Peto R, Henao-Restrepo A, et al. Repurposed antiviral drugs for Covid-19-interim WHO solidarity trial results. N. Engl. J. Med. 2020; 384: 497-511. https://doi.org/10.1056/NEJMoa2023184
15. Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020; 369:m1966. https://doi.org/10.1136/bmj.m1966
16. Chen P, Nirula A, Heller B, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med. 2021; 384:229-37. https://doi.org/10.1056/NEJMoa2029849
17. Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 2021; 384:238-51. https://doi.org/10.1056/NEJMoa2035002
18. Petrosillo N, Viceconte G, Ergonul O, et al. COVID-19, SARS and MERS: are they closely related? Clin. Microbiol. Infect. 2020; 26 (6):729-734. https://doi.org/10.1016/j.cmi.2020.03.026
19. Cutino‐Moguel C, Eades C, Rezvani K, et al. Immunotherapy for infectious diseases in haematological immunocompromised. Br. J. Haematol. 2017; 177(3):348-356. https://doi.org/10.1111/bjh.14595
20. Wang C, Li W, Drabek D, et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat. Commun. 2020; 11(10):2251. https://doi.org/10.1038/s41467-020-16256-y
21. Marovich M, Mascola J, Cohen M. Monoclonal antibodies for prevention and treatment of COVID-19. JAMA. 2020 https://doi.org/10.1001/jama.2020.10245
324 (2):131-132. doi:https://doi.org/10.1001/jama. 2020.10245.
22. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of 2019 novel coronavirus infection in China. N Engl J Med. 2020; 382(18):1708-1720. doi: https://doi.org/10.1056/NEJMoa2002032
23. Gorbalenya A, Andrey M. Anastasia A, et al. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 2020; 5:536-544. https://doi.org/10.1038/s41564-020-0695-z
24. Andersen KG, Rambaut A, Lipkin WI, et al. The proximal origin of SARS-CoV-2. Nat. Med. 2020; 26 (4):450-452. https://doi.org/10.1038/s41591-020-0820-9
25. Kan B, Wang M, Jing, H, et al. Molecular evolution analysis and geographic investigation of severe acute respiratory syndrome coronavirus-like virus in palm civets at an animal market and on farms. J. Virol. 2005; 79(18):11892-11900. https://doi.org/10.1128/JVI.79.18.11892-11900.2005
26. Young BE, Kalimuddin S, Loh J, et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA. 2020; 323(15):1488-1494. https://doi.org/10.1001/jama.2020.3204
27. Ceccarelli M, Berretta M, Rullo EV, et al. Editorial-Differences and similarities between Severe Acute Respiratory Syndrome (SARS)-CoronaVirus (CoV) and SARS-CoV-2. Would a rose by another name smell as sweet? Eur. Rev. Med. Pharmacol. Sci. 2020; 24(5): 2781-2783. doi: https://doi.org/10.26355/eurrev_202003_20551
28. Du L, He Y, Zhou Y, et al. The spike protein of SARS-CoV- a target for vaccine and therapeutic development. Nat. Rev. Microbiol. 2009; 7:226-236. https://doi.org/10.1038/nrmicro2090
29. Rota PA, Oberste MS, Monroe SS, et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science. 2003; 300(5624):1394-1399. https://doi.org/10.1126/science.1085952
30. Tortorici MA, Veesler D. Structural insights into coronavirus entry. Adv. Virus Res. 2019; 105:93-116. https://doi.org/10.1016/bs.aivir.2019.08.002
31. Lu RM, Hwang YC, Liu IJ, et al. Development of therapeutic antibodies for the treatment of diseases. J. Biomed. Sci. 2020; 27(1):1-30. https://doi.org/10.1186/s12929-019-0592-z
32. Walker LM , Burton DR. Passive immunotherapy of viral infections: super-antibodies enter the fray. Nat. Rev. Immunol. 2018; 18(5):297-308. https://doi.org/10.1038/nri.2017.148
33. Jiang S, Du L, Shi Z, et al. An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies. Emerg. Microbes Infect. 2020; 9(1):275-277. https://doi.org/10.1080/22221751.2020.1723441
34. Zhu Z, Chakraborti S, He Y, et al. Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc. Natl. Acad. Sci. 2007; 104(29):12123-12128. https://doi.org/10.1073/pnas.0701000104
35. Zhou Y, Yang Y, Huang J, et al. Advances in MERS-CoV vaccines and therapeutics based on the receptor-binding domain. Viruses. 2019; 11(1):60. https://doi.org/10.3390/v11010060
36. Tian X, Li C, Huang A, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg. Microbes Infect. 2020; 9 (1):382-385. https://doi.org/10.1080/22221751.2020.1729069
37. U.S. Food & Drug Administration. Coronavirus (COVID-19) update: FDA authorizes monoclonal antibodies for treatment of COVID-19. Available at: https://www.fda.gov/newsevents/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonalantibodies-treatment-covid-19. Published November 21, 2020.
38. Regeneron Pharmaceuticals Inc. Fact sheet for health care providers: emergency use authorization (EUA) of casirivimab and imdevimab. Available at: Regeneron https:// www.regeneron.com/sites/default/files/treatmentcovid19-eua-fact-sheet-for-hcp.pdf. Updated June 2021.
39. Gupta A, Juarez E, Moya J, et al. Early Covid-19 Treatment With SARS-CoV-2 Neutralizing Antibody Sotrovimab. BMJ. May 28, 2021. https://doi.org/10.1101/2021.05.27.21257096
40. Saunders KO. Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life. Front Immunol. 2019; 10:1296. https://doi.org/10.3389/fimmu.2019.01296
41. Bloch EM, Shoham S, Casadevall A, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020; 130(6):2757-2765. https://doi.org/10.1172/JCI138745
42. Wen J, Cheng Y, Ling R, et al. Antibody-dependent enhancement of coronavirus. Int J Infect Dis. 2020; 100:483-489. https://doi.org/10.1016/j.ijid.2020.09.015
43. Arvin AM, Fink K, Schmid MA, et al. A perspective on potential antibody-dependent enhancement of SARS-CoV-2. Nature. 2020; 584(7821):353-363. https://doi.org/10.1038/s41586-020-2538-8
44. Lee WS, Wheatley AK, Kent SJ, et al. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat Microbiol. 2020; 75(7):1699-1709. https://doi.org/10.1038/s41564-020-00789-5
45. Robbiani DF, Gaebler C, Muecksch F, et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020; 584:437-442. https://doi.org/10.1101/2020.05.13.092619
46. Baum A, Fulton BO, Wloga E, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020; 369(6506):1014-1018. https://doi.org/10.1126/science.abd0831
47. Ning L, Abagna HB, Jiang Q, et al. Development and application of therapeutic antibodies against COVID-19. Int. J. Biol. Sci. 2021; 17(6):1486-1496. https://doi.org/10.7150/ijbs.59149
48. Roche JA & Roche R, et al. A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications. FASEB J. 2020; 34(6):7265-7269. https://doi.org/10.1096/fj.202000967
49. He G, Massarella J, Ward P, et al. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin. Pharmacokinet. 1999; 37(6):471-484. https://doi.org/10.2165/00003088-199937060-00003
50. Guillon A, Pardessus J, Lhommet P, et al. Exploring the fate of inhaled monoclonal antibody in the lung parenchyma by microdialysis. PMC. 2019; 11(2):297-304. https://doi.org/10.1080/19420862.2018.1556081
51. Brainard J. Scientists are drowning in COVID-19 papers. Can new tools keep them afloat? Science. 2020. https://doi.org/10.1126/science.abc7839
52. Yang L, Liu W, Yu X, et al. COVID-19 antibody therapeutics tracker: a global online database of antibody therapeutics for the prevention and treatment of COVID-19. Antib Ther. 2020; 3(3):205-12. https://doi.org/10.1093/abt/tbaa020
53. Graham BS. Rapid COVID-19 vaccine development. Science. 2020; 368(6494):945-946. https://doi.org/10.1126/science.abb8923
54. Sparrow E, Friede M, Sheikh M, et al. Therapeutic antibodies for infectious diseases. Bull World Health Organ. 2017; 95 (3): 235-237. https://doi.org/10.2471/BLT.16.178061
55. World Health Organization. Guidelines on evaluation of monoclonal antibodies as similar biotherapeutic products (SBPs). Available at: https://www.who.int/biologicals/expert_committee/mAb_SBP_GLECBS_review_adoption-2016.10.26-11.7post_ECBS-Clean_Version. pdf.2016 (accessed 2 February 2021).
56. Gottlieb RL, Nirula A, Chen P, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2021; 325(7):632-644. https://doi.org/10.1001/jama.2021.0202
57. Regeneron Pharmaceuticals Inc. RECOVERY Trial Data Monitoring Committee recommends continuing evaluation of REGN-COV2 in all hospitalized patients. Available at: Regeneron https://investor.regeneron.com/newsreleases/news-release-details/recovery-trial-datamonitoring-committee-recommends-continuing (2020).
58. Wang C, Horby PW, Hayden FG et al. A novel coronavirus outbreak of global health concern. Lancet.2020; 395:470-473. https://doi.org/10.1016/S0140-6736(20)30185-9
59. Zhu N, Zhang D, Tan W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 2020; 382:727-733. https://doi.org/10.1056/NEJMoa2001017
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).